drugset / Trial / NCT01069120
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
RandomizedParallel-groupOpen-labelTreatment
Summary
Safety and efficacy study of 25 and 50 mg doses of Proellex
Timeline
- Start
- 2009-04
- Primary completion
- 2009-08
- Completion
- 2009-08
Outcome
Outcome not reported
Stopped: “Repros stopped study due to safety and FDA placed study on hold”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Proellex | Other / unclassified | 25 mg | — |
| Comparator | Proellex | Other / unclassified | 50 mg | — |